On March 9, 2021 Kiromic Biopharma, Inc. (Nasdaq: KRBP), a target discovery and gene-editing company utilizing artificial intelligence and its proprietary neural network platform with a therapeutic focus on immuno-oncology, reported the planned resubmission of two investigational new drug (IND) applications with the U.S. Food and Drug Administration (FDA) (Press release, Kiromic, MAR 9, 2021, View Source [SID1234576350]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The revised INDs will be for first in-human dosing of our Off-the-Shelf, Allogenic Gamma-Delta T cell therapy for metastatic and progressive locally advanced solid malignancies.
The revised INDs have protocols which retain approximately 80% of the original INDs. The differences between the INDs are detailed below:
Revised INDs
Original INDs
Enrollment
Open enrollment,
multiple solid tumors
Single enrollment
1 solid tumor (ovarian)
Administration
Only IV
Either IV or IP
Chimeric T cell therapies
Separate INDs
for 2 chimeric T cell therapies
IND-1: chPD1 (solid tumors, IV)
IND-2: Iso-Mesothelin (solid tumors, IV)
Separate INDs for
varying routes of administration
IND-1: chPD1 (ovarian, IV)
IND-2: chPD1 (ovarian, IP)
IND-3: Iso-Mesothelin (ovarian IV & IP)
BENEFITS
Shorten the time
required to reach full enrollment
Expanded potential future indications
** IV = Intravenous, IP = Intraperitoneal
Timelines for the planned two INDs:
— 2Q-2021, Expected timeline for planned two IND resubmissions
— 30 days, Expected review and return by the FDA post IND submissions
— 3Q-2021, Expected timeline of first-in-human dosing
— 4Q-2021, Expected timeline of first-in-human safety and efficacy data from the trial
Since filing the original INDs in December 2020, the Company has had many discussions with the FDA, and numerous consults with scientific board and clinical advisors regarding the changes listed above. These changes shown above were made to ensure the optimal chances for success for the planned clinical trials.
Open-Enrollment and Impact on Timing
"We believe the changes in the two revised IND’s are very positive for Kiromic. The open enrollment will add breast, prostate, colorectal, and lung to our existing ovarian cancer. It is expected that the change to an open enrollment will decrease the time to reach full enrollment," says Dr. Maurizio Chiriva-Internati, CEO of Kiromic.
Single Mode of Administration (IV)
"One of the most strategic modifications was the move to a single route of administration. The new INDs will have only IV administration versus previous INDs having IV and IP. IV administration reflects the dominant and preferred mode of administration for cancer therapies in the clinic today whereby intracavitary infusions are considered more invasive. The feedbacks from the clinical sites on the new IV administration and open enrollment have been very well received," commented Dr. Scott Dahlbeck, Chief Medical Officer of Kiromic.
** IV = Intravenous, IP = Intraperitoneal
Market Expansion with Multiple Solid Tumors
"Ovarian cancer is already a significant indication by itself. However, having multiple solid tumors that are eligible in our new open enrollment protocol, including cancers such as breast, prostate, colorectal, and lung for example, will only increase the potential applications of our Off-the-Shelf, Allogenic Gamma-Delta T cell therapies," says Mr. Gianluca Rotino, Chief of Strategy and Innovation of Kiromic.
GMP Facility Readiness
"Kiromic continues to prepare itself for the upcoming first in-human trials by making sure that its GMP manufacturing facility is ready, staffed, and fully equipped. Despite COVID and the recent ice-storms which made national news, Kiromic is still running daily batch testing and validations of our Off-the-Shelf, Allogenic Gamma-Delta T cell manufacturing in full preparation for the upcoming trial," says Mr. Tony Tontat, CFO and COO of Kiromic.
Upcoming Events
— Kiromic CEO interview on Bloomberg TV Europe (March 2021)
— Kiromic CEO, CFO presentation at Benzinga Small Cap Conference (Mar 25th, 2021)
— Kiromic Abstracts highlighting our AI Neoantigen discovery engine, and our Off-the-Shelf, Allogenic Gamma-Delta T cell manufacturing at AACR (Free AACR Whitepaper) 2021 conference (April 9-14, 2021). www.aacr.org